||Fludarabine, a DNA synthesis inhibitor, is a chemotherapy drug used in the treatment of hematological malignancies.
||Dimethyloxallyl glycine is a cell permeable competitive inhibitor of HIF-PH HIF-1 prolyl hydroxylase
||LY294002 is the first synthetic molecule known to inhibit p110α, p110β and p110δ with IC50 of 0.5 μM, 0.57 μM, 0.97 μM.
||LY364947 is a potent ATP-competitive inhibitor of TGFR-I with IC50 of 59 nM, exhibits 7-fold selectivity over TGFR-II.
||Mizoribine is an immunosuppressive agents (IC50=100 μM) that inhibit the proliferation of lymphocytes selectively, via inhibition of IMPDH.
||Perifosine is an Akt inhibitor with IC50 of 4.7 μM, targets pleckstrin homology domain of Akt.
||U0126 ethanol is a highly selective inhibitor of MEK1/2 with IC50 of 70/60nM.
||Veliparib is a potent inhibitor of PARP1 and PARP2 with Ki of 52 nM and 29 nM respectively
||Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley.
||Tozasertib is the inhibitor of Aurora-A, -B, -C kinases with Ki values of 0.6, 18, 4.6 nM respectively.
||Ruxolitinib is the first potent, selective, JAK12 inhibitor to enter the clinic with IC50 of 3.3 nM2.8 nM, 130-fold selectivity for JAK12 versus JAK3
||Panobinostat is a broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay.
||ABT-263 is a potent inhibitor of Bcl-xL Bcl-2 and Bcl-w with Ki ≤ 0.5nM, ≤1 nM and ≤1 nM in cell-free assays.
||CHIR-99021 is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM, exhibiting > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, a
||Alectinib is a potent ALK inhibitor with IC50 of 1.9 nM while also inhibits F1174L, R1275Q, and L1196M mutants of ALK (IC50s 1.0, 3.5, and 1.6 nM, re
||GSK126 is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, > 1000-fold selective for EZH2 over 20 other human methyltr
||ABT-199 is a Bcl-2-selective inhibitor with Ki of 0.01 nM, 4800-fold selective versus Bcl-xL and Bcl-w, and showing no activity to Mcl-1.
||AS7-03026 is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5-2000nM in MM cell lines.
||Abemaciclib Methanesulfonate is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM respectively, used for the treatment of
||Copanlisib is a potent and highly selective reversible PI3K inhibitor for PI3Kα/β with IC50 of 0.469 nM/3.72 nM.
||LY3009120 is a small molecule that has been shown to be a pan-RAF inhibitor of all isoforms inhibiting BRAFV600E BRAFWT and CRAFWT with IC50 values of
||SCR7 pyrazine is a specific DNA ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).
||GDC-0068 is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA.
||LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential a
||AZD1208 is an orally bioavailable highly selective PIM kinases inhibitor with single nanomolar potency against all three PIM kinases IC50 of 04 nM 5 n
||Palbociclib HCl is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein
||EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM 200-fold selective for c-Met than IRAK4 TrkA Axl IRAK1 and Mer
||Tideglusib is an irreversible GSK-3 inhibitor with IC50 of 5 nM and 60 nM for GSK-3WT (1 h preincubation) and GSK-3C199A (1 h preincubation), respecti
||Pracinostat is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6 and has no activity against the class III isoenzyme SIRT I.
||AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor of GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows > 14-fold se
||PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM.
||SD-208 is a potent, orally active ATP-competitive transforming growth factor- receptor 1 (TGF-RI) inhibitor (IC50 49 nM) and displays 100-fold and 1
||Everolimus is a mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.
||KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 13 and 22 nM respectively and highly selective for ATM as compared to DNA-PK PI3KPI4K ATR an
||SGI-1776 free base is an ATP competitive inhibitor of Pim1 with IC50 of 7 nM in a cell-free assay 50- and 10-fold selective versus Pim2 and Pim3 also
||SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM, showing 150-fold selectivity over CXCR1 and four other 7-TMRs.
||Pexidartinib is a small-molecule receptor tyrosine kinase RTK inhibitor of KIT CSF1R and FLT3 with IC50s of 20 10 and 160 nM in vitro respectively
||CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respec
||BAY 87-2243 is a highly potent and selective inhibitor of hypoxia-induced HIF-1 activation
||Dinaciclib is a potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.
||RGFP966 is an HDAC3 inhibitor with IC50 of 008 M in cell-free assay exhibits 200-fold selectivity over other HDAC
||SIS3 is an inhibitor of Smad3 and can inhibit TGF-β and activin signaling without affecting other pathways.
||Afuresertib is a potent orally bioavailable Akt inhibitor with Ki of 008 nM 2 nM and 26 nM for Akt1 Akt2 and Akt3 respectively
||LY2109761 is a selective TGF- receptor type III (TRIII) dual inhibitor with Ki of 38 nM and 300 nM, respectively and is shown to negatively affect the
||SMI-4a is a potent inhibitor of Pim1 with IC50 of 17 nM modestly potent to Pim-2 does not significantly inhibit any other serinethreonine- or tyrosine
||Salubrinal is a selective inhibitor of eukaryotic translation initiation factor 2 subunit eIF2 dephosphorylation
||Quisinostat dihydrochloride is a second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 011 nM in a cell-free assay modest poten
||OTX-015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4 in cell-free assays.
||Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-134, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4
||2-methoxyestradiol is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 μM for the inhibition of BPAEC